ZayaAI
Romanian AI startup ZayaAI, leading developments in machine learning, expanding R&D team, collaborating with experts, and creating an AI-based method for mycobacteria identification in pathology diagnosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 669 % | 152 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 33 % | 7 % | (75 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ZayaAI is a Romanian digital pathology company founded in 2020 by Cristian Mogodici, an MBA and serial entrepreneur; Sabina Zurac, a distinguished senior pathologist and professor; and Mihai Trăscău, an AI expert and university lecturer. The founders' collective expertise in business, pathology, and artificial intelligence forms the foundation of the company's mission to address the global shortage of pathologists and enhance diagnostic accuracy. ZayaAI operates in the digital pathology and telepathology market, which was valued at $2 billion in 2021 and is projected to experience significant growth.
The firm develops artificial intelligence solutions to improve the speed and precision of disease diagnosis from medical images. Its business model targets hospitals, private medical clinics, pathology labs, and pharmaceutical companies. Revenue is generated through various subscription plans, including corporate, individual, and exclusive 'Zaya Club' memberships, providing different levels of access to its medical services. The company's ecosystem is designed around three core components: Zaya Artificial Intelligence, Zaya Medical Clinic, and Zaya Pathology Lab.
ZayaAI's product suite includes 'ZayaAI Dx', an AI-powered tool that assists pathologists by analyzing tissue and cell images to detect diseases like tuberculosis and various cancers. Another key product, 'ZayaAI Telepathology Dx', is a cloud-based platform that facilitates remote consultations and second opinions among medical professionals globally, improving access to specialist expertise. Complementing these is the 'ZayaAI Pathology LIS', a Laboratory Information System designed to streamline lab workflows from sample tracking to reporting. The company leverages a vast database of approximately 500,000 cases and millions of tissue images to train its deep learning models, which have demonstrated performance comparable to human experts. The technology aims to reduce laboratory costs by 30% and accelerate diagnosis times threefold.
Keywords: digital pathology, artificial intelligence, medical diagnostics, telepathology, cancer diagnosis, laboratory information system, healthcare technology, machine learning, pathology workflow, medical imaging